Dasiglucagon, a next‐generation ready‐to‐use glucagon analog, for treatment of severe hypoglycemia in children and adolescents with type 1 diabetes: Results of a phase 3, randomized controlled trial

BACKGROUND: Dasiglucagon, a next‐generation, ready‐to‐use aqueous glucagon analog formulation, has been developed to treat severe hypoglycemia in individuals with diabetes. OBJECTIVE: The aim of this trial was to evaluate the safety and efficacy of dasiglucagon in pediatric individuals with type 1 d...

Descripción completa

Detalles Bibliográficos
Autores principales: Battelino, Tadej, Tehranchi, Ramin, Bailey, Timothy, Dovc, Klemen, Melgaard, Anita, Yager Stone, Jenine, Woerner, Stephanie, von dem Berge, Thekla, DiMeglio, Linda, Danne, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons A/S 2021
Materias:
Clinical Care and Technology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8361970/
https://www.ncbi.nlm.nih.gov/pubmed/33934456
http://dx.doi.org/10.1111/pedi.13220

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8361970/
https://www.ncbi.nlm.nih.gov/pubmed/33934456
http://dx.doi.org/10.1111/pedi.13220

Ejemplares similares